Startups
Verseau’s lead product targets PSGL-1 (P-selectin glycoprotein ligand-1), which is an adhesion molecule involved in immune cell trafficking in response to tissue injury or inflammation, according to the company.
Plexium is focused on developing therapeutics that influence E3 ligases that can degrade proteins, even the undruggable ones. The company’s founder and chief executive officer Kandaswamy “Swamy” Vijayan, took time out to speak with BioSpace about the company and its technology platform, DELPHe.
ArsenalBio will focus on integrating various technologies, including CRISPR, synthetic biology, and machine learning to discover and develop immunotherapies, initially for oncology.
Adaptate will build on GammaDelta’s expertise in modulating gammadelta T-cell activity using antibodies, with a focus on developing an immune response to cancer.
Cygnal was founded in 2017 based on discoveries made in the field of exoneural biology, which is a new understanding of how nerves and neural signaling drive human health and disease.
We’re proud to announce the launch of the Research on Research Institute – an international consortium of research funders, academic institutions, and technologists working to champion the latest approaches to research on research.
Epigenetics is the study of changes in gene expression that don’t involve changes to the DNA sequence.
Trucode’s triplex gene-editing technology uses proprietary synthetic peptide nucleic acid oligomers and DNA correction sequences to edit disease-causing mutations by harnessing natural DNA repair mechanisms.
Nearly one year after it was launched by Pfizer and Bain Capital, Cerevel Therapeutics has tapped industry veteran Tony Coles as its chief executive officer.
MaRS Innovation is pleased to announce that, on its 10th anniversary, it has changed its name to Toronto Innovation Acceleration Partners to reflect its refined focus on venture building and growth to advance its Members’ health science innovations .
PRESS RELEASES